Our work is more urgent than ever and is reaching more people, but we can’t do it without you. Please consider subscribing today and join us in our mission to promote science and innovation for the betterment of society and the world as a whole.
Pioneering gene therapy may treat a deadly seizure disorder
The latest breakthrough in gene therapy offers hope for treating a rare and often fatal seizure disorder known as Dravet syndrome. The new drug, zorevunersen, has shown promising results in clinical trials, especially for patients who do not respond well to traditional treatments like antiseizure medications.
Dravet syndrome is a devastating condition that typically manifests in early childhood, leading to frequent seizures and cognitive impairment. Tragically, a significant percentage of children with Dravet syndrome do not survive into adulthood. Current treatment options, which include antiseizure drugs and specialized diets, often fall short in controlling the seizures associated with the disorder. According to Helen Cross, a senior author of the study from University College London, achieving seizure-free status is rare among patients with Dravet syndrome.
Zorevunersen differs from conventional treatments by targeting the underlying genetic mutation responsible for Dravet syndrome, specifically the SCN1A gene. In a study involving 81 patients in the U.S. and U.K., the drug demonstrated a remarkable reduction in seizure frequency and an improvement in overall quality of life. Over a 20-month period, patients experienced between 59% and 91% fewer seizures compared to before starting the treatment, with most side effects being mild to moderate.
The medication, classified as an antisense oligonucleotide, works by preventing the degradation of essential proteins encoded by the SCN1A gene. By modifying the instructions for protein synthesis within cells, zorevunersen addresses the root cause of the disease rather than just managing its symptoms. Early indications suggest that the drug not only reduces seizures but also enhances communication, motor skills, and cognitive function in patients with Dravet syndrome.
Veronica Hood, the chief science officer of the Dravet Syndrome Foundation, lauded the results as unprecedented and transformative for individuals living with the condition. The ongoing phase 3 trial aims to further evaluate the drug’s efficacy in treating core symptoms of Dravet syndrome and solidify its potential as a game-changer in the field of genetic therapy.
Lori Isom, a researcher at the University of Michigan involved in the drug’s development, expressed emotional reactions to the positive outcomes observed in patients, highlighting the potential for zorevunersen to revolutionize the long-term prognosis for individuals with Dravet syndrome. Ingrid Scheffer, a pediatric neurologist at the University of Melbourne specializing in Dravet syndrome, echoed these sentiments, emphasizing the life-altering impact of the medication on patients’ quality of life.
The promising results of the zorevunersen trials offer renewed hope for individuals and families affected by Dravet syndrome, showcasing the transformative power of gene therapy in addressing rare and challenging genetic disorders. As research in this field continues to advance, the prospects for personalized treatments tailored to specific genetic mutations are becoming increasingly within reach, heralding a new era in precision medicine for genetic conditions. In today’s world, where the importance of science and research has never been more crucial, it is essential for us to stand up and show why science matters. One way you can support this mission is by gifting someone a subscription to a scientific journal or publication.
By gifting a subscription, you are not only providing someone with access to cutting-edge research and information but also supporting the scientific community as a whole. Scientific journals play a vital role in disseminating new discoveries, advancements, and breakthroughs in various fields of study. By subscribing to these publications, you are helping to fund and sustain the important work that scientists do every day.
In times like these, when the world is facing numerous challenges and uncertainties, it is more important than ever to support scientific research and education. By gifting a subscription, you are empowering someone to stay informed, educated, and engaged with the latest developments in their field of interest.
Whether you are passionate about biology, chemistry, physics, or any other scientific discipline, there is a subscription out there that will cater to your interests. From academic journals to popular science magazines, there is a wide range of options to choose from. You can even customize the subscription based on the recipient’s preferences and interests.
So why not show your support for science and research by gifting someone a subscription today? Your gesture will not only be appreciated by the recipient but will also make a meaningful contribution to the advancement of knowledge and understanding in our world.
There has never been a more important time for us to stand up and show why science matters. I hope you’ll support us in that mission by gifting a subscription to someone who shares your passion for science and discovery. Together, we can make a difference and ensure that the importance of science is recognized and valued by all.

